Steady Start to 2022; FY 2022 Constant Currency Revenue Growth Guidance Reaffirmed BOSTON, United States and LAUSANNE, Switzerland, May 10, 2022 — SOPHiA GENETICS SA (Nasdaq: SOPH), a leader in data-driven medicine, today reported financial results for the first...
Diversity in Genomic Analysis: An example of how SOPHiA GENETICS has built more accurate health data analysis for diverse populations
Every person is unique. We can clearly see this within the more than one million genomic profiles from 70 different countries analyzed by our technology.
BOSTON, United States and LAUSANNE, Switzerland – May 5, 2022 – SOPHiA GENETICS (Nasdaq: SOPH), a leader in data-driven medicine, today announced the nomination of Jean-Michel Cosséry to its Board of Directors. The Board of Directors will propose the...
Third party sequencing services can enable increased access to NGS testing, but if institutions do not receive access to the raw data it can limit the insights they can gain. Doing the data analysis in house can allow you to harness the power of genomic data to reveal relevant variants.
SOPHiA GENETICS has reached a major milestone on a global scale by analyzing one million genomic profiles.
BOSTON, United States and LAUSANNE, Switzerland – April 26, 2022 – SOPHiA GENETICS (Nasdaq: SOPH), a leader in data-driven medicine, has reached the milestone of one million genomic profiles analyzed by its SOPHiA DDM™ Platform, securing its position...
Q&A with the Clinical Application Product Manager, Mikhail Pertziger, PhD
Next generation sequencing has greatly enhanced our power for identifying mutations associated with myeloid malignancies. However, accurate and timely detection of complex variants can be challenging.
Read our summary of top-rated research in the field of exome sequencing at the American College
of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting 2022.